itive Breast Cancer HR-Positive Breast CancerHR-Positive Breast CancerHarold J. Burstein
Background: The combination of CDK4/6 inhibitors (CDK4/6i) and endocrine therapy (ET) is currently the standard first-line treatment for patients with metastatic hormone receptor positive (HR+), and HER2-negative (HER2-) breast cancer. However, the impact of HER2 status...
Hormone Receptor Positive Breast Cancer resource centreTamoxifen has a key role in the management of women with hormone receptor (HR) positive breast cancer. It is the endocrine treatment of choice in premenopausal women with HR positive breast cancer and is also clinically indicated in significant ...
The long-sought discovery of HER2 as an actionable and highly sensitive therapeutic target was a major breakthrough for the treatment of highly aggressive HER2-positive breast cancer, leading to approval of the first HER2-targeted drug — the monoclonal antibody trastuzumab — almost 25 years ago....
If yourbreast cancerhas a significant number of receptors for either estrogen or progesterone, it’s considered hormone-receptor positive. Tumors that are ER/PR-positive are much more likely to respond to hormone therapy than tumors that are ER/PR-negative. ...
[15]Datopotamab deruxtecan (Dato-DXd) vs chemotherapy (CT) in previously treated inoperable or metastatic hormone receptor-positive, HER2-negative (HR+/HER2–) breast cancer (BC): Patient-reported outcomes (PROs) from the TROPION-Breast01 study.2024 ASCO 1006 ...
According to our results, TGNs has shown great binding capacities with HER2-positive breast cancers, and TGN-mediated photothermal therapy has led to a selective destruction of HER2 positive breast cancer cells, which is similar to the results of former studies10,35. Although it seems like gold ...
[1]Giuseppe C, Xichun H, Rebecca A, et al. Trastuzumab deruxtecan (T-DXd) vs physician’s choice of chemotherapy (TPC) in patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor...
in patients with HER2-positive early-stage breast cancer. The 2-year invasive disease-free survival (DFS) rate was 93.9% in the neratinib arm versus 91.6% with placebo, representing a 33% reduction in the risk of recurrence (HR = 0.67; 95% CI, 0.50-0.91;P= .009). However, 95.4% of...
Transcript:Adam M. Brufsky, MD, PhD:So, we’re going to turn now to hormone receptor-positive metastatic breast cancer, and start with data that are being presented at ESMO 2016, and go from there. Michael, the FALCON trial is being presented actually today at ESMO. Can you start with...